Slingshot Insights recently conducted an interview with Dr. Ashwin Balagopal, assistant professor of medicine at the Johns Hopkins University School of Medicine about the impact that Dynavax Technologies Corporation DVAX 2.03%’s HBV-23 will have on the HBV vaccine market, particularly when it comes to GlaxoSmithKline plc (ADR) GSK 0.91%’s Engerix-B.
When asked about the Phase III Dynavax data that was released in January, Dr. Balagopal said that it looks very promising.
“What I’ve seen of the data that were released is that the Dynavax vaccine appears to be as effective if not more effective, at least in the generation of protective antibody fighters for hepatitis B prevention, after only 2 doses,” Dr. Balagopal explained. “Having it be two doses rather than three doses is certainly preferable because you’re going to miss a lot of people for whom you’re insisting on three doses.”
When asked about the potential market share that a Dynavax vaccine could achieve, Dr. Balagopal said…
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!